Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.

ABSTRACT:

Purpose

¹⁸F-fluoroestradiol (FES) PET scans measure regional estrogen binding, and ¹⁸F-fluorodeoxyglucose (FDG) PET measures tumor glycolytic activity. We examined quantitative and qualitative imaging biomarkers of progression-free survival (PFS) in breast cancer patients receiving endocrine therapy.

Experimental design

Ninety patients with breast cancer from an estrogen receptor-positive (ER⁺), HER2^- primary tumor underwent FES PET and FDG PET scans prior to endocrine therapy (63% aromatase inhibitor, 22% aromatase inhibitor and fulvestrant, 15% other). Eighty-four had evaluable data for PFS prediction.

Results

Recursive partitioning with 5-fold internal cross-validation used both FES PET and FDG PET measures to classify pa

SUBMITTER: Kurland BF 

PROVIDER: S-EPMC5183531 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature